HETERO - Walk-In interview in formulation for QC department on 23rd May 2015 @ Hyderabad
About Hetero Pharma:-
Hetero is one of India's leading generic drug companies for the treatment of HIV / AIDS and is the world's largest anti-retroviral drug. Supported by more than 25 years of expertise in pharmaceutical industry, Hetero's strategic business field spreads in APIs, generic, bio-chemiers, custom pharmaceutical services and branded generics. The company is recognized globally for research, development, production and commercialization of a wide range of products.
There are 36 state-of-the-art manufacturing facilities in the field of Etterro, which are tested and approved by strict regulatory authorities like US FDA, EU, TGA-Australia, MCC-South Africa and others. Our portfolio includes 300 plus products, including major therapeutic categories like HIV / AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology.
There is a strong global presence in 126 countries and focuses on making medicines accessible to patients worldwide.
Dr. B. S. S. Reddy had an interest in ensuring good health for all those who founded Hetero in 1993. A visionary scientist, Dr. BPS Reddy had tremendous leadership experience in the field of research and development, production and marketing with leading pharmaceutical companies.
His scientific expertly helped guide research to achieve success, due to the increase in his business, he became a world leader with strong potential in Hetero creation and marketing.
Dr. B. P. S. Under the leadership of Reddy, Hitro has become the closest drug company in India. This is known as a global leader in the production of renowned anti-retroviral drugs to offer high quality medicines in major treatments.
At Heathrow, quality is a factor that we greatly appreciate and tries to preserve it at every level. We give proof of our claim of sanctioning by the strict global regulatory authority.
And each of our production facilities is sophisticated with state-of-the-art quality systems and processes that fully comply with CGMP (the current good production transaction).
The Quality Control Lab equipped with high-precision equipment ensures that excellence in the production process is retained. Also, the highest standards are followed for health, safety and environmental practices.
It is said that you know from the company that you hold. We can not agree more at Hetero. Over the past few years, we have established a productive alliance and long-term partnership with leading global pharma organizations, which depend on our preparation of medicines with the highest expenditure-efficiency. Thanks to our robust R & B and backward-integration capabilities that present meaningful meaningful benefits. In addition, we have also succeeded in helping our partners launch many first-time generic in major therapeutic areas.
Our global cooperation with renovation companies has allowed us to continually increase our product basket and influence global markets, our partnership with the global shopping agency helps us increase access to life-saving medicines worldwide.
Heterollas are the major global supply disorders of anti-retroviral drugs. We have HIV / AIDS, Oncology, Cardiovascular, Neurology etc. Global leaders are also involved in the development and production of complete formulations, with a broad portfolio of more than 200 products in various therapeutic categories.
In addition to the ability to deliver products in various dosage forms, including solid and liquid oral dosage, pre-filled syringe, injextables, controlled-release and multi-layer tablet, we are best in hot melt electrification, palatalization and Spronization process. Our full dosage is created in 21 dedicated dedicated features which are approved and audited by world regulatory authorities.
Having two decades of experience in developing an API in a variety of therapeutic areas. In fact, we're one of the first Indian companies to create and build Affordable APIs for ARVs. Our portfolio covers more than 300 APIs, which include different segments.
Our 15 special production companies are aggregated and have a large number of production capabilities that enable us to create a large number of APIs for regulating and semi-regulated markets. We have also introduced identification as an ideal name for launching many first-time generic launches.
